Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sichuan Baili Pharmaceutical Co., Ltd.
University of Washington
Eli Lilly and Company
GOG Foundation
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Instituto do Cancer do Estado de São Paulo
Mersana Therapeutics
AbbVie
Corcept Therapeutics
Imunon
University of Colorado, Denver
Dana-Farber Cancer Institute
Imunon
Regeneron Pharmaceuticals
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Genmab
Mayo Clinic
AbbVie
AstraZeneca
H. Lee Moffitt Cancer Center and Research Institute
Memorial Sloan Kettering Cancer Center
Centre Oscar Lambret